Form 8-K - Current report:
SEC Accession No. 0001104659-23-026404
Filing Date
2023-02-28
Accepted
2023-02-28 08:19:41
Documents
16
Period of Report
2023-02-28
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm238017d1_8k.htm   iXBRL 8-K 25229
2 EXHIBIT 99.1 tm238017d1_ex99-1.htm EX-99.1 17557
6 GRAPHIC tm238017d1_ex99-1img001.jpg GRAPHIC 1018390
7 GRAPHIC tm238017d1_ex99-1img002.jpg GRAPHIC 892764
8 GRAPHIC tm238017d1_ex99-1img003.jpg GRAPHIC 986449
  Complete submission text file 0001104659-23-026404.txt   4216402

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tbph-20230228.xsd EX-101.SCH 3039
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20230228_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tbph-20230228_pre.xml EX-101.PRE 22599
10 EXTRACTED XBRL INSTANCE DOCUMENT tm238017d1_8k_htm.xml XML 3639
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 23678554
SIC: 2834 Pharmaceutical Preparations